Kapital til iværksættere
November 26, 2011
Undertegnede har stor erfaring med at skaffe kapital til iværksætter-virksomheder. Dette gælder både finansiering fra investorer til egne iværksætter-projekter men også som konsulent hvor jeg har hjulpet andre iværksættere med at skaffe kapital fra business angels, venture kapital fonde og offentlige fonde.
På Kapitalblog.dk deler vi ud af vores erfaringer med at skaffe kapital til iværksættere.
Discount rates in drug development
January 26, 2011
Together with AVANCE, BIOSTRAT Biotech Consulting has completed an analysis in which it is determined which discount rates industry professionals in pharma and biotech are applying when doing financial valuations in drug development.
The 242 respondents in the survey are widely distributed across the key biotech industry stakeholder groups in biotech/pharma valuations (consultants, bankers, investors, biotech and pharma professionals).
The respondents were presented with three case companies, all biotech companies within cancer drug development but in different stages: One early-stage company where the lead drug candidate is in pre-clinical development, one mid-stage company where the lead candidate is in Phase III, and finally a late-stage company where the lead candidate is in Phase III.
The average discount rates applied to these three cases are:
- Early-stage: 23.7 %
- Mid-stage: 17.4 %
- Late-stage: 14.6 %
Please find the full analysis by following this link
Valuation methods and discount rates in Biotech
November 19, 2009
Which discount rate and which valuation method to use is a hot topic when making financial valuations of biotech projects and biotech companies.
Discount rates and valuation methods for biotech companies has been the subject of much theorizing. Methods as DCF, rNPV, and Real Options are methods known to most industry professionals.
When discussing the issue of valuation of biotech projects/companies with other professionals, it becomes clear that there are many different opinions regarding what is the ”correct” method and discount rate to use.
We have therefore prefarred a survey on valuation mathods for biotech companies. This survey is NOT about what you think is the right (theoretical) method and the right discount rate.
Rather the purpose is to gain a better understanding of which discount rates and methods are actually used by professionals around the world, and thus to give industry professionals a better overview of the different view-points in biotech valuation.
PARTICIPATE IN THE SURVEY HERE
The survey takes less than 10 minutes to complete. All respondents will receive the summary report on the survey findings free of charge.
Thank you for your participation
Best Regards,
Nicolaj Højer Nielsen
Important to distinguish between the short-term and longer-term effects of the credit crisis
November 30, 2008
Analysts are advising investors to stay away from biotech companies in urgent need of capital. Goldman Sachs is predicting that as many as half of European biotech companies may fail due to the current credit crisis.
We agree biotech companies having to raise capital in the next 12 months will either be forced do so at the expense of shareholder value as a result of a lower valuation. Or they will not be able to raise capital at all. Other biotech companies, with limited financial resources, will need to conserve cash by closing/delaying a large part of their pipeline. We have already seen a number of Scandinavian biotech companies do so, and others will follow suit in the months to come. Those are the short-term effect of the credit crisis.
In the longer term we foresee an acceleration of the emerging trend towards more extensive and strategic partnerships between biotech- and pharmaceutical companies. Most biotech companies will find it harder, even in the medium- to long run, to raise capital and will be forced to look for alternative ways of financing their operation. At the same time many pharmaceutical companies are faced with blockbuster products coming to the end of their patent protection. Those companies need to focus much of their attention and efforts on feeding their pipeline.
These developments work to highlight the fact that the relationship between biotechs and pharma companies is co-evolutionary in nature. Like hummingbirds and flowers they have become dependent on each other and each others’ resources for their long-term survival.
The biologist will speak about how such species have grown ’structurally coupled’ to each other - how they are determining each other over time. Same is true for the relationship between biotechs and pharmaceuticals, only we humans have the added capacity for developing strategic tools for formalizing and optimizing such process of co-evolution. In this case those tools are: partnerships, alliances and M&As and we predict these tools will be employed more in the future.
The current credit crisis will act to strengthening the structural coupling between biotechs and pharmaceutical companies and that is the real and longer-term effect of this current crisis.
Best regards,
Nicolaj Højer Nielsen, Managing Director
BIOSTRAT BIOTECH CONSULTING
Good news for Medicon Valley
June 5, 2008
This week brought two good news for the biotech industry in Medicon Valley and the entire Nordic region:
SwedenBio, the industry association for Swedish biotech companies, announced the yearly survey of the pharmaceutical pipeline in Sweden. The results are promissing - the drug development pipeline in Sweden has increased with 32 projects since 2007. A total number of 142 pharmaceutical drugs are now in development in Swedish biotech and life-science companies. The projects have also matured since last year so a total of 15 projects are now in phase II, compared to only 11 projects in 2007. You can download the full report here.
But the week also brough good news for the Danish biotech industry: Ernst & Young published their yearly analysis of the global biotech industry, with promissing conclusions seen from a Danish point of view. The number of products under development in Denmark increased with 25 % compared to last year, compared to a growth of “only” 9 % in Europe as a whole. According to Ernst & Young the Danish pipeline now consists of 188 products with Germany and Great Britain as the only two European countries with a larger pipeline than the Danish biotech industry! You can download the full report here.